Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

RE104 Sikkerheds- og Effektivitetsundersøgelse ved Generaliseret Angstlidelse

21. september 2026 opdateret af: Reunion Neuroscience Inc

En randomiseret, dobbeltblind, placebokontrolleret undersøgelse, der evaluerer sikkerheden og effekten af RE104 til injektion i behandlingen af generaliseret angstlidelse

The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.

Studieoversigt

Status

Rekruttering

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

160

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

  • Navn: Mark Pollack Chief Medical Officer, M.D.
  • Telefonnummer: 1-888-880-REUN
  • E-mail: info@reunionneuro.com

Studiesteder

    • Alabama
      • Birmingham, Alabama, Forenede Stater, 35209
        • Rekruttering
        • University of Alabama (UAB) Clinical Research Unit (CRU)
        • Kontakt:
    • Arizona
      • Gilbert, Arizona, Forenede Stater, 85234
    • Arkansas
      • Little Rock, Arkansas, Forenede Stater, 72211
    • California
      • Garden Grove, California, Forenede Stater, 92845
        • Rekruttering
        • Collaborative Neuroscience Research, LLC
        • Kontakt:
      • La Jolla, California, Forenede Stater, 92037
        • Rekruttering
        • Kadima Neuropsychiatry Institute
        • Kontakt:
      • San Francisco, California, Forenede Stater, 94114
      • Santa Monica, California, Forenede Stater, 90404
    • Florida
      • Lauderhill, Florida, Forenede Stater, 33319
        • Rekruttering
        • Innovative Clinical Research, Inc.
        • Kontakt:
      • Tampa, Florida, Forenede Stater, 33613
        • Rekruttering
        • University of South Florida
        • Kontakt:
    • Georgia
      • Atlanta, Georgia, Forenede Stater, 30331
        • Rekruttering
        • Atlanta Center for Medical Research
        • Kontakt:
      • Decatur, Georgia, Forenede Stater, 30030
      • Norcross, Georgia, Forenede Stater, 30092
      • Savannah, Georgia, Forenede Stater, 31405
        • Rekruttering
        • CenExel iResearch, LLC
        • Kontakt:
    • Illinois
      • Chicago, Illinois, Forenede Stater, 60640
    • Michigan
      • Novi, Michigan, Forenede Stater, 48377
        • Rekruttering
        • Henry Ford Medical Center - Columbus
        • Kontakt:
    • Missouri
      • Saint Charles, Missouri, Forenede Stater, 63304
    • New Mexico
      • Albuquerque, New Mexico, Forenede Stater, 14624
        • Rekruttering
        • UNM Research Program Psychedelic Therapies
        • Kontakt:
    • New York
      • New York, New York, Forenede Stater, 10016
        • Rekruttering
        • NYU-H+C Clinical and Translational Science Institute
        • Kontakt:
    • North Carolina
      • Chapel Hill, North Carolina, Forenede Stater, 27514
    • Ohio
      • North Canton, Ohio, Forenede Stater, 44720
        • Rekruttering
        • Neuro-Behavioral Clinical Research, Inc.
        • Kontakt:
    • Oregon
    • Pennsylvania
      • Philadelphia, Pennsylvania, Forenede Stater, 19104
      • West Chester, Pennsylvania, Forenede Stater, 19380
        • Trukket tilbage
        • Suburban Research Associates
    • Texas
      • Austin, Texas, Forenede Stater, 78737
        • Rekruttering
        • Austin Clinical Trial Partners
        • Kontakt:
      • Austin, Texas, Forenede Stater, 78759
      • Plano, Texas, Forenede Stater, 75093
    • Utah
      • Draper, Utah, Forenede Stater, 84020
      • Orem, Utah, Forenede Stater, 84058

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 74 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Has Generalized Anxiety Disorder as defined by DSM-5-TR
  • If female is not pregnant or planning to become pregnant. If male is not planning to make a partner pregnant.
  • Is willing and able to comply with the conditions and requirements of the study

Exclusion Criteria:

  • Has a significant risk of suicide
  • Has an active or medical history of bipolar disorder, schizophrenia, schizoaffective disorder, psychotic disorder and/or borderline personality disorder, or first-degree family history of psychosis or bipolar disorder
  • Has other concurrent psychiatric disorders that is the primary disorder.
  • Has other medically significant conditions rendering unsuitability for the study
  • Has used or will need to use prohibited medications or therapies
  • Has a known sensitivity or intolerance to study intervention or potential rescue medications

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: Randomiseret
  • Interventionel model: Parallel tildeling
  • Maskning: Tredobbelt

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Placebo komparator: Placebo

A single subcutaneous injection of 0.9% sodium chloride for injection per dosing session

Single-dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of 0.9% sodium chloride for injection

Eksperimentel: 30 mg RE104

A single subcutaneous injection of 30 mg RE104 for Injection per dosing session

Single dose (Part A) or Repeat-dose (Part B), subcutaneous injection(s) of RE104 for Injection

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
RE104 when administered as a single 30 mg dose or as two 30 mg doses 3 weeks apart versus placebo change from Baseline at Week 4 in Hamilton Anxiety Rating Scale (HAM-A) total score
Tidsramme: Week 4

The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.

Week 4

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
RE104 versus placebo changes in total score from baseline in Hamilton Anxiety Rating Scale (HAM-A)
Tidsramme: Weeks 1, 2, 8 and 12

The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.

Weeks 1, 2, 8 and 12
RE104 versus placebo percentage of participants with HAM-A response (≥50% reduction in score from Baseline)
Tidsramme: Weeks 1, 2, 4, 8 and 12

The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.

Weeks 1, 2, 4, 8 and 12
RE104 versus placebo percentage of participants with HAM-A remission (total score ≤7)
Tidsramme: Day 1 and Weeks 1, 2, 4, 8 and 12

The Hamilton Rating Scale for Anxiety (HAM-A) is a 14-item scale that is used to rate the severity of symptoms of anxiety. The total score ranges from 0-56 with higher scores representing greater severity of anxiety.

Day 1 and Weeks 1, 2, 4, 8 and 12
RE104 versus placebo change from Baseline at Weeks 1, 2, 4, 8, and 12 in Hospital Anxiety and Depression Scale (HADS) depression subscore
Tidsramme: Weeks 1, 2, 4, 8 and 12

The Hospital Anxiety and Depression Scale (HADS) is a self-reported scale measure the severity of depression and anxiety in patients with comorbid medical conditions. The scale consists of 14 items (7 for anxiety and 7 for depression), with a score ranging between 0 and 21 for the anxiety and depression subscales.

Weeks 1, 2, 4, 8 and 12
RE104 versus placebo incidence of treatment-emergent adverse events (TEAEs) by frequency, severity and seriousness.
Tidsramme: From dosing through study completion (post-dose follow-up is for 12 weeks)

A treatment-emergent adverse event (TEAE) is defined as any unfavorable and unintended sign, symptom or disease temporally associated with the use of a study drug.

From dosing through study completion (post-dose follow-up is for 12 weeks)
RE104 versus placebo change from Baseline in Montgomery-Åsberg Depression Rating Scale (MADRS) (Part B only)
Tidsramme: Weeks 1, 2, 4, 8, and 12

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a 10-item clinician rated scale measuring depression severity. The total score ranges from 0-60 with higher scores representing greater severity of depression.

Weeks 1, 2, 4, 8, and 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Efterforskere

  • Studieleder: Mark Pollack, M.D., Reunion Neuroscience Inc

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

20. april 2026

Primær færdiggørelse (Anslået)

1. juli 2027

Studieafslutning (Anslået)

1. september 2027

Datoer for studieregistrering

Først indsendt

18. marts 2026

Først indsendt, der opfyldte QC-kriterier

18. marts 2026

Først opslået (Faktiske)

24. marts 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

24. september 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

21. september 2026

Sidst verificeret

1. september 2026

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Andre undersøgelses-id-numre

  • RE104-203-GAD

Plan for individuelle deltagerdata (IPD)

Planlægger du at dele individuelle deltagerdata (IPD)?

INGEN

IPD-planbeskrivelse

Data sharing will be consistent with the results submission policy of ClinicalTrials.gov.

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ja

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner